Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumoursthe MACBETH project

Cazzaniga, Marina E.ASST Monza, Phase 1 Trials Res Unit, Monza, MB, Italy; ASST Monza, Oncol Unit, Monza, MB, Italy; Milano Bicocca Sch Med, Monza, MB, Italy (author)

Metastatic or locally advanced breast cancer patients : towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumoursthe MACBETH project

Introduction: Despite the large use of nab-paclitaxel as a treatment option in metastatic breast cancer (MBC) across different countries, no definitive data are available in particular clinical situations.Areas covered: Efficacy, safety and schedule issues concerning available literature on nab-paclitaxel in advanced breast cancer and in specific subgroups of patients have been discussed and voted during an International Expert Meeting. Ten expert specialists in oncology, with extensive clinical experience on Nab-P and publications in the field of MBC have been identified. Six scientific areas of interest have been covered, generating 13 specific Statements for Nab-P, after literature review. For efficacy issues, a summary of research quality was performed adopting the GRADE algorithm for evidence scoring. The panel members were invited to express their opinion on the statements, in case of disagreement all the controversial opinions and the relative motivations have been made public.Expert opinion: Consensus was reached in 30.8% of the Nab-P statements, mainly those regarding safety issues, whereas ones regarding efficacy and schedule still remain controversial areas, requiring further data originated by the literature.

Ciruelos, E.Ctr Integral Oncol Clara Campal HM CIOCC, Unidad Canc Mama, Madrid, Spain (author)
Fabi, A.Regina Elena Inst Canc Res, Med Oncol, Rome, Italy (author)
Garcia-Saenz, J.Hosp Clin San Carlos, ISCIII, IdISSC CIBERONC, Dept Med Oncol, Madrid, Spain (author)
Lindman, HenrikUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)henrlind (author)
Mavroudis, D.Univ Hosp Heraklion, Dept Med Oncol, Iraklion, Crete, Greece (author)
Schem, C.Mammazentrum, Hamburg, Germany (author)
Steger, G.Med Univ Vienna, Dept Internal Med 1, Vienna, Austria (author)
Timotheadou, E.Aristotle Univ Thessaloniki, Sch Med, Papageorgiou Gen Hosp, Thessaloniki, Greece (author)
Zaman, K.Univ Hosp CHUV, Dept Oncol, Breast Ctr, Lausanne, Switzerland (author)
Torri, V.Ist IRCCS Ist Mario Negri, Milan, Italy (author)
ASST Monza, Phase 1 Trials Res Unit, Monza, MB, Italy; ASST Monza, Oncol Unit, Monza, MB, Italy; Milano Bicocca Sch Med, Monza, MB, ItalyCtr Integral Oncol Clara Campal HM CIOCC, Unidad Canc Mama, Madrid, Spain (creator_code:org_t)

In:Cancer Chemotherapy and Pharmacology: Springer Science and Business Media LLC83:2, s. 301-3180344-57041432-0843

By the author/editor: Cazzaniga, Marin ...; Ciruelos, E.; Fabi, A.; Garcia-Saenz, J.; Lindman, Henrik; Mavroudis, D.; show more...; Schem, C.; Steger, G.; Timotheadou, E.; Zaman, K.; Torri, V.; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cancer and Oncol ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.